Sutro Biopharma, Inc. (STRO)
9.33
-0.96
(-9.33%)
USD |
NASDAQ |
Oct 23, 16:00
9.335
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Net Income (Quarterly) : -38.53M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.53M |
| March 31, 2026 | -38.48M |
| December 31, 2025 | -46.76M |
| September 30, 2025 | -56.86M |
| June 30, 2025 | -11.50M |
| March 31, 2025 | -75.97M |
| December 31, 2024 | -72.44M |
| September 30, 2024 | -48.79M |
| June 30, 2024 | -48.02M |
| March 31, 2024 | -58.21M |
| December 31, 2023 | 31.06M |
| September 30, 2023 | -49.28M |
| June 30, 2023 | -38.52M |
| March 31, 2023 | -50.05M |
| December 31, 2022 | -34.59M |
| September 30, 2022 | -19.49M |
| June 30, 2022 | -26.01M |
| Date | Value |
|---|---|
| March 31, 2022 | -39.11M |
| December 31, 2021 | -38.12M |
| September 30, 2021 | -30.90M |
| June 30, 2021 | -6.152M |
| March 31, 2021 | -30.36M |
| December 31, 2020 | -59.54M |
| September 30, 2020 | 17.14M |
| June 30, 2020 | 29.87M |
| March 31, 2020 | -19.60M |
| December 31, 2019 | -14.79M |
| September 30, 2019 | -12.91M |
| June 30, 2019 | -13.79M |
| March 31, 2019 | -14.25M |
| December 31, 2018 | -1.493M |
| September 30, 2018 | -10.24M |
| December 31, 2017 | -15.34M |
| September 30, 2017 | -1.418M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Upstream Bio, Inc. | -39.70M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.839M |
| Total Expenses (Quarterly) | 48.37M |
| EPS Diluted (Quarterly) | -2.325 |
| Enterprise Value | 240.16M |
| Gross Profit Margin (Quarterly) | 87.17% |
| Profit Margin (Quarterly) | -391.6% |
| Earnings Yield | -186.6% |
| Normalized Earnings Yield | -174.24 |